COVID-19 and systemic thrombotic syndromes

COVID-19 is one of the most dangerous diseases of the current decade that has significantly affected the overall morbidity, mortality, quality of health and life of global population. Among multiple early and late post-COVID complications observed in patients with a new coronavirus infection, perhaps the main place is held by thrombosis. The significant role of microthrombosis, disseminated intravascular coagulation, thrombotic angiopathies in COVID-19 pathogenesis is noted. The accumulated data from clinical studies and the presented expert opinions made it possible to establish the significance of the "immunothrombosis–NETosis–thromboinflammation" relationship in the pathological effects caused by SARS-CoV-2 virus, as well as to reveal the mechanisms underlying formation of thrombotic syndromes mediated by anticoagulant therapy and vaccination. The information obtained about hemostasis disorders allows to move deeper into understanding the long-term sequelae in COVID-19 convalescent patients.